TimesSquare Capital Management LLC Purchases 42,226 Shares of Axon Enterprise, Inc $AXON

TimesSquare Capital Management LLC lifted its position in Axon Enterprise, Inc (NASDAQ:AXON) by 34.2% in the 4th quarter, Holdings Channel reports. The fund owned 165,530 shares of the biotechnology company’s stock after acquiring an additional 42,226 shares during the quarter. Axon Enterprise accounts for 1.4% of TimesSquare Capital Management LLC’s holdings, making the stock its 11th biggest holding. TimesSquare Capital Management LLC’s holdings in Axon Enterprise were worth $94,009,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Resona Asset Management Co. Ltd. raised its position in shares of Axon Enterprise by 17.8% in the 4th quarter. Resona Asset Management Co. Ltd. now owns 122,358 shares of the biotechnology company’s stock worth $69,988,000 after acquiring an additional 18,506 shares in the last quarter. AF Advisors Inc. bought a new position in shares of Axon Enterprise in the 4th quarter worth approximately $302,000. Profund Advisors LLC raised its position in shares of Axon Enterprise by 6.1% in the 4th quarter. Profund Advisors LLC now owns 6,989 shares of the biotechnology company’s stock worth $3,969,000 after acquiring an additional 403 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Axon Enterprise by 38.4% in the 4th quarter. ProShare Advisors LLC now owns 137,521 shares of the biotechnology company’s stock worth $78,102,000 after acquiring an additional 38,183 shares in the last quarter. Finally, North Dakota State Investment Board bought a new position in shares of Axon Enterprise in the 4th quarter worth approximately $1,451,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $399.37 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $32.19 billion, a P/E ratio of 160.39, a PEG ratio of 9.22 and a beta of 1.44. The stock’s 50 day moving average is $428.80 and its 200 day moving average is $511.32. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.01. The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.47 EPS. On average, equities research analysts predict that Axon Enterprise, Inc will post 1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Erika Nardini sold 198 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total value of $100,302.84. Following the sale, the director owned 1,946 shares in the company, valued at $985,804.68. This represents a 9.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the sale, the insider owned 55,588 shares in the company, valued at $29,740,135.88. The trade was a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,855 shares of company stock worth $7,109,828 over the last three months. Corporate insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Citizens Jmp decreased their target price on Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a research report on Thursday, May 7th. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. UBS Group decreased their target price on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. increased their target price on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.